Lightning AI: Business owner report
Expanded web report · Related PDF snapshot: 22 October 2026 · PDF page 8
Research reviewed 22 October 2026 · Evidence and editorial planning guidance are distinguished below.
Choose the investment and accept the residual risk
Evaluate the commercial dependence on the platform and the reach of the access entrusted to it. The immediate priority is controlled recovery; a later supplier review should examine exportability, separation of identities and the cost of maintaining a usable alternative.
Your immediate priorities
- Fund connected-account investigation as well as workspace restoration.
- Ask for a business continuity option that can operate without the original Studio login.
How to work through the decision
Compare the cost of interruption, response and sustained improvement separately. Use your actual trading volumes, staff costs and contractual commitments; this report supplies no universal loss estimate. Identify who can approve emergency spending and who can accept a temporary exception. A supplier change should have measurable acceptance criteria, retained responsibilities and an exit route, rather than an assumption that a brand eliminates risk.
Evidence to ask for
A recovery decision covering delivery impact, downstream exposure and a tested alternative path.
Could the business recover its essential work if the development platform stayed unavailable?
Work with the next person
Give the business manager a clear continuity priority, spending authority and escalation threshold. Ask for unresolved decisions and evidence gaps, not only a red, amber or green status.
Continue with the business manager report for this topic.
A scenario to rehearse
Illustrative exercise, not an observed customer incident: A team regains access to its development workspace but has not reviewed the repository token and cloud role stored there. The exercise separates workspace availability from the status of those external identities.
What a useful outcome looks like
A recovery decision covering delivery impact, downstream exposure and a tested alternative path. Keep the decision dated and return to it if new evidence changes the scope.